当前位置: 首页 >> 检索结果
381. Longitudinal trends in health-related quality of life in adults with cystic fibrosis.
作者: Edward J Dill.;Ree Dawson.;Deborah E Sellers.;Walter M Robinson.;Gregory S Sawicki.
来源: Chest. 2013年144卷3期981-989页
Health-related quality-of-life (HRQOL) measures have been used as patient-reported outcomes in clinical trials in cystic fibrosis (CF), but there are limited data on HRQOL changes over time in adults with CF.
382. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.
作者: Stavros Apostolakis.;Renee M Sullivan.;Brian Olshansky.;Gregory Y H Lip.
来源: Chest. 2013年144卷5期1555-1563页
When oral anticoagulation with adjusted-dose vitamin K antagonist (VKA) is used, the quality of anticoagulation control (as reflected by the time in therapeutic range [TTR] of the international normalized ratio [INR]) is an important determinant of thromboembolism and bleeding. Our objective was to derive a validated scheme using patient-related clinical parameters to assess the likelihood of poor INR control among patients with atrial fibrillation (AF) on VKA therapy.
383. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
作者: Victor F Tapson.;Zhi-Cheng Jing.;Kai-Feng Xu.;Lei Pan.;Jeremy Feldman.;David G Kiely.;Eugene Kotlyar.;C Shane McSwain.;Kevin Laliberte.;Carl Arneson.;Lewis J Rubin.; .
来源: Chest. 2013年144卷3期952-958页
Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy. Treprostinil diolamine, a sustained-release oral formulation of treprostinil, was studied to determine whether it could provide a more convenient prostacyclin treatment option for patients with less severe PAH. The objective of this study was to evaluate the efficacy and safety of oral treprostinil in patients with PAH receiving stable background endothelin receptor antagonist (ERA), phosphodiesterase type 5 inhibitor (PDE-5I) therapy, or both.
384. Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial.
作者: Rodrigo P Pedrosa.;Luciano F Drager.;Lílian K G de Paula.;Aline C S Amaro.;Luiz A Bortolotto.;Geraldo Lorenzi-Filho.
来源: Chest. 2013年144卷5期1487-1494页
OSA is extremely common among patients with resistant hypertension (HTN). However, the impact of the treatment of OSA with CPAP on BP in patients with resistant HTN is not well established.
385. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
作者: Gilles Garcia.;Antoine Magnan.;Raphaël Chiron.;Cécile Contin-Bordes.;Patrick Berger.;Camille Taillé.;Gilles Devouassoux.;Frédéric de Blay.;Louis-Jean Couderc.;Alain Didier.;Dermot S O'Callaghan.;Pierre-Olivier Girodet.;Isabelle Bourdeix.;Vincent Le Gros.;Marc Humbert.
来源: Chest. 2013年144卷2期411-419页
While up to 50% of patients with severe asthma have no evidence of allergy, IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE monoclonal antibody, is reported to significantly benefit a subset of patients with severe, persistent, allergic asthma. Therefore, we investigated whether omalizumab has biologic and clinical effects in patients with refractory nonatopic asthma.
386. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial.
作者: Christopher B Cooper.;Bartolome R Celli.;José R Jardim.;Robert A Wise.;Daniel Legg.;Junhai Guo.;Steven Kesten.
来源: Chest. 2013年144卷2期490-497页
Disease progression in COPD is associated with a decline in exercise performance over time. We assessed whether tiotropium might mitigate this by determining its effect on treadmill endurance time (ET) over 2 years.
387. Acute bronchodilator responsiveness to tiotropium in postinfectious bronchiolitis obliterans in children.
作者: Mariângela F C Teixeira.;Joaquim C Rodrigues.;Claudio Leone.;Fabíola V Adde.
来源: Chest. 2013年144卷3期974-980页
Patients with postinfectious bronchiolitis obliterans (PIBO) usually have severe airflow obstruction and respond poorly to β-adrenergic drugs. However, the bronchodilator response to an anticholinergic agent such as tiotropium bromide is not known. We studied the acute bronchodilator response to tiotropium for up to 24 h in children with PIBO using spirometric and plethysmographic criteria.
388. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis.
Cough is a pervasive and disabling symptom of idiopathic pulmonary fibrosis (IPF) and is an independent predictor of disease progression. The Cough Quality-of-Life Questionnaire (CQLQ) is a validated measure of cough-specific quality of life that could be used as an outcome measure in therapeutic trials for IPF. This study aimed to assess the reliability and validity of the CQLQ in individuals with IPF.
389. A prospective study of respiratory viral infection in pregnant women with and without asthma.
作者: Vanessa E Murphy.;Heather Powell.;Peter A B Wark.;Peter G Gibson.
来源: Chest. 2013年144卷2期420-427页
Respiratory viral infections are common in pregnancy, but their health impact, especially in asthma, is unknown. The objective of this study was to assess the frequency, severity, and consequences of respiratory viral infection during pregnancy in women with and without asthma.
390. New dedicated bifurcated silicone stent placement for stenosis around the primary right carina.
Silicone stenting has been widely used to palliate respiratory symptoms in patients suffering from airway stenosis. Although many types and shapes of stents have been developed, there is no ideal stent for stenosis around the carina between the bronchus to the right upper lobe and the bronchus intermedius (primary right carina). The purpose of this study was to evaluate the feasibility, efficacy, and safety of a new silicone stent designed for treating airway stenosis around the primary right carina.
391. Sex-dependent impact of OSA on digital vascular function.
作者: Anna Randby.;Silje K Namtvedt.;Harald Hrubos-Strøm.;Gunnar Einvik.;Virend K Somers.;Torbjørn Omland.
来源: Chest. 2013年144卷3期915-922页
Indexes of associations between OSA and impaired vascular function are mainly based on small, clinic-based studies of conduit artery function in men with severe sleep apnea. Larger population-based studies show no independent associations or associations in women only. Sex differences in OSA-related mortality may exist, and sex differences in vascular function in subjects with OSA need to be explored. We, therefore, assessed whether OSA is associated with digital vascular function in a large population-based sample and whether this association is influenced by sex.
392. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.
作者: Ivan F N Hung.;Kelvin K W To.;Cheuk-Kwong Lee.;Kar-Lung Lee.;Wing-Wa Yan.;Kenny Chan.;Wai-Ming Chan.;Chun-Wai Ngai.;Kin-Ip Law.;Fu-Loi Chow.;Raymond Liu.;Kang-Yiu Lai.;Candy C Y Lau.;Shao-Haei Liu.;Kwok-Hung Chan.;Che-Kit Lin.;Kwok-Yung Yuen.
来源: Chest. 2013年144卷2期464-473页
Experience from influenza pandemics suggested that convalescent plasma treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust treatment data are lacking.
393. The Epworth Sleepiness Scale: conventional self vs physician administration.
作者: Mario Francesco Damiani.;Vitaliano Nicola Quaranta.;Vito Antonio Falcone.;Felice Gadaleta.;Michele Maiellari.;Teresa Ranieri.;Francesco Fanfulla.;Pierluigi Carratù.;Onofrio Resta.
来源: Chest. 2013年143卷6期1569-1575页
The Epworth Sleepiness Scale (ESS) is a simple, self-administered questionnaire that provides a measurement of the subject's level of daytime sleepiness, and is widely used for patients with obstructive sleep apnea (OSA). Some works undermined its accuracy. The aim of this study was to compare self-administered ESS scores to physician-administered scores in a sample of patients with suspicion of OSA.
394. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
作者: Diana Bilton.;Evangelia Daviskas.;Sandra D Anderson.;John Kolbe.;Gregory King.;Rob G Stirling.;Bruce R Thompson.;David Milne.;Brett Charlton.; .
来源: Chest. 2013年144卷1期215-225页
Inhaled dry powder mannitol enhanced mucus clearance and improved quality of life over 2 weeks in non-cystic fibrosis bronchiectasis. This study's objective was to investigate the efficacy and safety of dry powder mannitol over 12 weeks.
395. Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
作者: Steven M Rowe.;Ginger Reeves.;Heather Hathorne.;G Martin Solomon.;Smita Abbi.;Didier Renard.;Ruth Lock.;Ping Zhou.;Henry Danahay.;John P Clancy.;David A Waltz.
来源: Chest. 2013年144卷1期200-207页
Prostasin, a trypsin-like serine protease, is a channel-activating protease and major regulator of epithelial sodium channel-mediated sodium absorption. Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF).
396. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.
作者: William B White.;Glen E Cooke.;Peter R Kowey.;Peter M A Calverley.;Dirk Bredenbröker.;Udo-Michael Goehring.;Haiyuan Zhu.;Hassan Lakkis.;Hans Mosberg.;Paul Rowe.;Klaus F Rabe.
来源: Chest. 2013年144卷3期758-765页
Evaluation of cardiovascular safety for new therapies for COPD is important because of a high prevalence of cardiac comorbidities in the COPD population. Hence, we evaluated the effects of roflumilast, a novel oral phosphodiesterase 4 inhibitor developed for the treatment and prevention of COPD exacerbations, on major adverse cardiovascular events (MACEs).
397. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.
作者: Gianluca Campo.;Paolo Guastaroba.;Antonio Marzocchi.;Andrea Santarelli.;Elisabetta Varani.;Luigi Vignali.;Pietro Sangiorgio.;Stefano Tondi.;Carlotta Serenelli.;Rossana De Palma.;Francesco Saia.
来源: Chest. 2013年144卷3期750-757页
There are limited data describing the long-term outcome of patients with concomitant COPD who develop ST-segment elevation myocardial infarction (STEMI).
398. Effects of experimental sleep restriction on caloric intake and activity energy expenditure.
作者: Andrew D Calvin.;Rickey E Carter.;Taro Adachi.;Paula G Macedo.;Felipe N Albuquerque.;Christelle van der Walt.;Jan Bukartyk.;Diane E Davison.;James A Levine.;Virend K Somers.
来源: Chest. 2013年144卷1期79-86页
Epidemiologic studies link short sleep duration to obesity and weight gain. Insufficient sleep appears to alter circulating levels of the hormones leptin and ghrelin, which may promote appetite, although the effects of sleep restriction on caloric intake and energy expenditure are unclear. We sought to determine the effect of 8 days/8 nights of sleep restriction on caloric intake, activity energy expenditure, and circulating levels of leptin and ghrelin.
399. Arm elevation and coordinated breathing strategies in patients with COPD.
作者: Thomas E Dolmage.;Tania Janaudis-Ferreira.;Kylie Hill.;Shirley Price.;Dina Brooks.;Roger S Goldstein.
来源: Chest. 2013年144卷1期128-135页
Hyperinflated patients with COPD breathe against an increased elastic load during physical activity. Arm activities are especially demanding. Some pulmonary rehabilitation programs instruct patients to inhale while raising their arms, whereas others recommend the opposite. This study aimed to determine the effect of coordinating breathing with arm movements on the endurance of a lifting task.
400. Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS.
We hypothesized that nebulized iloprost would improve ventilation-perfusion matching in patients with pulmonary hypertension and ARDS as reflected by an improved Pao2/Fio2 ratio and Pao2 without adversely affecting lung mechanics or systemic hemodynamics.
|